CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics

CytomX Therapeutics, Inc. (CTMX): $1.54

0.02 (+0.99%)

POWR Rating

Component Grades














  • Value is the dimension where CTMX ranks best; there it ranks ahead of 69.61% of US stocks.
  • CTMX's strongest trending metric is Stability; it's been moving down over the last 177 days.
  • CTMX ranks lowest in Momentum; there it ranks in the 4th percentile.

CTMX Stock Summary

  • Of note is the ratio of CYTOMX THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 10.52% of US stocks have a lower such ratio.
  • For CTMX, its debt to operating expenses ratio is greater than that reported by just 14.47% of US equities we're observing.
  • With a year-over-year growth in debt of -20.83%, CYTOMX THERAPEUTICS INC's debt growth rate surpasses merely 14.18% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CYTOMX THERAPEUTICS INC are SIMO, IKNA, PIRS, SYBX, and VTGN.
  • Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to

CTMX Valuation Summary

  • In comparison to the median Healthcare stock, CTMX's EV/EBIT ratio is 104.55% lower, now standing at -0.3.
  • Over the past 91 months, CTMX's price/earnings ratio has gone up 11.7.

Below are key valuation metrics over time for CTMX.

Stock Date P/S P/B P/E EV/EBIT
CTMX 2023-03-24 1.6 3.9 -1.2 -0.3
CTMX 2023-03-23 1.6 3.9 -1.1 -0.3
CTMX 2023-03-22 1.6 4.0 -1.2 -0.3
CTMX 2023-03-21 1.7 4.2 -1.2 -0.4
CTMX 2023-03-20 1.7 4.3 -1.2 -0.4
CTMX 2023-03-17 1.7 4.3 -1.3 -0.4

CTMX Growth Metrics

    The 3 year cash and equivalents growth rate now stands at -14.07%.
  • Its 3 year revenue growth rate is now at -5.43%.
  • The 3 year net cashflow from operations growth rate now stands at -30.48%.
CTMX's revenue has moved up $5,523,000 over the prior 15 months.

The table below shows CTMX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 71.943 -140.586 -97.593
2022-06-30 72.615 -136.442 -96.881
2022-03-31 70.738 -130.404 -91.94
2021-12-31 69.573 -119.031 -83.609
2021-09-30 66.219 -105.266 -72.082
2021-06-30 66.42 -100.244 -64.208

CTMX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTMX has a Quality Grade of D, ranking ahead of 22.16% of graded US stocks.
  • CTMX's asset turnover comes in at 0.169 -- ranking 210th of 682 Pharmaceutical Products stocks.
  • JNJ, LEXX, and ORGS are the stocks whose asset turnover ratios are most correlated with CTMX.

The table below shows CTMX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.169 1 -0.872
2021-03-31 0.170 1 -0.944
2020-12-31 0.255 1 -0.424
2020-09-30 0.237 1 -0.610
2020-06-30 0.219 1 -0.636
2020-03-31 0.200 1 -0.554

CTMX Price Target

For more insight on analysts targets of CTMX, see our CTMX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.5 (Moderate Buy)

CTMX Stock Price Chart Interactive Chart >

Price chart for CTMX

CTMX Price/Volume Stats

Current price $1.54 52-week high $3.02
Prev. close $1.52 52-week low $1.17
Day low $1.46 Volume 1,238,200
Day high $1.58 Avg. volume 2,731,597
50-day MA $2.26 Dividend yield N/A
200-day MA $1.76 Market Cap 101.66M

CytomX Therapeutics, Inc. (CTMX) Company Bio

CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.

CTMX Latest News Stream

Event/Time News Detail
Loading, please wait...

CTMX Latest Social Stream

Loading social stream, please wait...

View Full CTMX Social Stream

Latest CTMX News From Around the Web

Below are the latest news stories about CYTOMX THERAPEUTICS INC that investors may wish to consider to help them evaluate CTMX as an investment opportunity.

What Does The Future Hold For CytomX Therapeutics, Inc. (NASDAQ:CTMX)? These Analysts Have Been Cutting Their Estimates

The analysts covering CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) delivered a dose of negativity to shareholders today...

Yahoo | March 29, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday!

William White on InvestorPlace | March 28, 2023

AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners

CytomX Therapeutics Inc (NASDAQ: CTMX) will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc (NYSE: ABBV) decided not to advance the drug into additional studies. CytomX and AbbVie have also concluded their research activities under a 2016 Discovery License and Collaboration Agreement. AbbVie paid $30 million upfront in 2016 to ink the deal and another $15 million in milestones in 2017 for the start of toxicology studies. Related: CytomX Shares Move Higher

Yahoo | March 28, 2023

CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -100% and 94.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 27, 2023

CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

- Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 - - Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®, BMS-986288, from Phase 1 to Phase 2 clinical evaluation as lead, next-generation CTLA-4 program - - Continued progress in strategic alliances including first clinical candidate milestone in Probody T-Ce

Yahoo | March 27, 2023

Read More 'CTMX' Stories Here

CTMX Price Returns

1-mo -28.37%
3-mo -3.75%
6-mo 6.21%
1-year -44.40%
3-year -77.01%
5-year -94.59%
YTD -3.75%
2022 -63.05%
2021 -33.89%
2020 -21.18%
2019 -44.97%
2018 -28.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0051 seconds.